High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases

Modern Pathology

Volumn 27, Issue 5, 2014, Pages 731-739

  Jang, Sejin ^a   Chun, Sung Min ^a   Hong, Seoung Mo ^a   Sung, Chang Ohk ^a   Park, Hosub ^a   Kang, Hyo Jeong ^a   Kim, Kyu Pyo ^a   Lee, Young Joo ^a   Yu, Eunsil ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

cholangiocarcinoma; chronic advanced liver disease; EGFR; high throughput massspectrometry; KRAS; mutation profile; survival

Indexed keywords

APC PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; GNAS PROTEIN; K RAS PROTEIN; NRAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN; PROTEIN MLH1; PROTEIN P53; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; GNAS PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MLH1 PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CHRONIC ADVANCED LIVER DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; LIVER DISEASE; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; MUTATION RATE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION; BILE DUCT TUMOR; GENETICS; INTRAHEPATIC BILE DUCT; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GTP PHOSPHOHYDROLASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; LIVER DISEASES; MALE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899968820     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.194     Document Type: Article

References (31)

1. Yamamoto M, Ariizumi S. Surgical outcomes ofintrahepatic cholangiocarcinoma. Surg Today 2011;41:896-902.
2. Guglielmi A, Ruzzenente A, Campagnaro T, et al.Intrahepatic cholangiocarcinoma: prognostic factorsafter surgical resection. World J Surg 2009;33:1247-1254.
3. Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis forintrahepatic cholangiocarcinoma after surgical treatment.J Gastrointest Surg 2011;15:608-613.
4. Gwak GY, Yoon JH, Shin CM, et al. Detection ofresponse-predicting mutations in the kinase domain ofthe epidermal growth factor receptor gene in cholangiocarcinomas.J Cancer Res Clin Oncol 2005;131:649-652.
5. Andersen JB, Spee B, Blechacz BR, et al. Genomicand genetic characterization of cholangiocarcinomaidentifies therapeutic targets for tyrosine kinaseinhibitors. Gastroenterology 2012;142:1021-1031;e1015.
6. Blechacz B, Komuta M, Roskams T, et al. Clinicaldiagnosis and staging of cholangiocarcinoma. Nat RevGastroenterol Hepatol 2011;8:512-522.
7. Razumilava N, Gores GJ. Classification, diagnosis, andmanagement of cholangiocarcinoma. Clin GastroenterolHepatol 2013;11:13-21; e11; quiz e13-14.
8. Nakanuma Y, Curabo MP, Granceschi S. Intrahepaticcholangiocarcinoma, 4th ed. IARC Press 2010.
9. Lee TY, Lee SS, Jung SW, et al. Hepatitis B virusinfection and intrahepatic cholangiocarcinoma inKorea: a case-control study. Am J Gastroenterol2008;103:1716-1720.
10. Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virusinfection as a likely etiology of intrahepatic cholangiocarcinoma.Cancer Sci 2004;95:592-595.
11. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factorsfor intrahepatic and extrahepatic cholangiocarcinoma:a hospital-based case-control study. Am J Gastroenterol2007;102:1016-1021.
12. Xu J, Igarashi S, Sasaki M, et al. Intrahepaticcholangiocarcinomas in cirrhosis are hypervascularin comparison with those in normal livers. Liver Int2012;32:1156-1164.
13. Nakanuma Y, Xu J, Harada K, et al. Pathologicalspectrum of intrahepatic cholangiocarcinoma arisingin non-biliary chronic advanced liver diseases. PatholInt 2011;61:298-305.
14. MacConaill LE, Campbell CD, Kehoe SM, et al. Profilingcritical cancer gene mutations in clinical tumorsamples. PLoS One 2009;4:e7887.
15. Weir BA, Woo MS, Getz G, et al. Characterizing thecancer genome in lung adenocarcinoma. Nature2007;450:893-898.
16. Arcila M, Lau C, Nafa K, et al. Detection of KRAS andBRAF mutations in colorectal carcinoma roles forhigh-sensitivity locked nucleic acid-PCR sequencingand broad-spectrum mass spectrometry genotyping.J Mol Diagn 2011;13:64-73.
17. Ong CK, Subimerb C, Pairojkul C, et al. Exomesequencing of liver fluke-associated cholangiocarcinoma.Nat Genet 2012;44:690-693.
18. Voss JS, Holtegaard LM, Kerr SE, et al. Molecularprofiling of cholangiocarcinoma shows potential fortargeted therapy treatment decisions. Hum Pathol2013;44:1216-1222.
19. Deshpande V, Nduaguba A, Zimmerman SM, et al.Mutational profiling reveals PIK3CA mutations ingallbladder carcinoma. BMC Cancer 2011;11:60.
20. Leone F, Cavalloni G, Pignochino Y, et al. Somaticmutations of epidermal growth factor receptor in bileduct and gallbladder carcinoma. Clin Cancer Res2006;12:1680-1685.
21. Reinersman JM, Johnson ML, Riely GJ, et al. Frequencyof EGFR and KRAS mutations in lung adenocarcinomasin African Americans. J Thorac Oncol 2011;6:28-31.
22. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologiccharacteristics of the EGFR gene mutation in non-smallcell lung cancer. J Thorac Oncol 2006;1:231-239.
23. Nakatani K, Takao M, Nishioka J, et al. Association ofepidermal growth factor receptor mutations in lungcancer with chemosensitivity to gefitinib in isolatedcancer cells from Japanese patients. Eur J Cancer Care(Engl) 2007;16:263-267.
24. Valle J, Wasan H, Palmer DH, et al. Cisplatin plusgemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med 2010;362:1273-1281.
25. Maheswaran S, Sequist LV, Nagrath S, et al. Detectionof mutations in EGFR in circulating lung-cancer cells.N Engl J Med 2008;359:366-377.
26. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalizedmedicine in non-small-cell lung cancer: is KRAS auseful marker in selecting patients for epidermalgrowth factor receptor-targeted therapy? J Clin Oncol2010;28:4769-4777.
27. Imel EA, Econs MJ. Fibrous dysplasia, phosphatewasting and fibroblast growth factor 23. PediatrEndocrinol Rev 2007;4(Suppl 4):434-439.
28. Shaikh D, Zhou Q, Chen T, et al. cAMP-dependentprotein kinase is essential for hypoxia-mediated epithelial-mesenchymal transition, migration, and invasion inlung cancer cells. Cell Signal 2012;24:2396-2406.
29. Tannapfel A, Benicke M, Katalinic A, et al. Frequencyof p16(INK4A) alterations and K-ras mutations inintrahepatic cholangiocarcinoma of the liver. Gut2000;47:721-727.
30. Sasaki M, Yamaguchi J, Itatsu K, et al. Over-expressionof polycomb group protein EZH2 relates to decreasedexpression of p16 INK4a in cholangiocarcinogenesis inhepatolithiasis. J Pathol 2008;215:175-183.
31. Taniai M, Higuchi H, Burgart LJ, et al. p16INK4apromoter mutations are frequent in primary sclerosingcholangitis (PSC) and PSC-associated cholangiocarcinoma.Gastroenterology 2002;123:1090-1098.